Surovatamig (AZD0486, TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNgamma, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma[1][2].
Molecular Weight:
(110.46 kDa)
Purity:
99.89
CAS Number:
[2892667-02-4]
Target:
CD19,CD3,IFNAR,Interleukin Related,TNF Receptor
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
